恒瑞医药 (600276)

Jiangsu Hengrui Pharmaceuticals Co., Ltd.

ASH

Tags

300ESG Index300 Non-Cyclical IndexAI HealthcareMSCI China A 50 IndexMSCI Component StocksSSE 180 IndexSSE 50 IndexSSE Corporate Governance IndexSSE Mega Cap IndexChina A80 IndexCSI 100 IndexCSI A100 IndexCSI A50 IndexCSI Leading Enterprises IndexGeneric DrugsImmunotherapyWeight Loss DrugsAnalyst Recommended StocksInnovation 100 IndexInnovative DrugsNorthbound Heavy PositionsPharmaceutical ManufacturingPharmaceuticals and HealthcareContains H-SharesEmployee Stock OwnershipBuyback PlansFund Heavy PositionsLarge Cap StocksCCTV 50 IndexFTSE China A50 IndexInvestment ClockEmerging Markets IndexPrivate Enterprises 100 IndexCSI 300 IndexConsumption 100 IndexHigh-Performing StocksMargin Trading and Securities LendingChina Securities Finance and Central Huijin HoldingsAssisted ReproductionTongdaxin 88Galaxy 99 IndexNon-Cyclical Stocks医药生物Chemical Pharmaceuticals

K-Line Chart

No K-line data available

Company NameJiangsu Hengrui Medicine Co., Ltd.
Listing Date2000-10-18
Issue Price11.98RMB
Registered Capital660352.207410k RMB
Legal RepresentativeSun Piaoyang
Registered AddressNo. 38 Huanghe Road, Economic and Technological Development Zone, Lianyungang City, Jiangsu Province
IndustryChemical Pharmaceuticals
Main BusinessDrug R&D, production and sales
Company ProfileJiangsu Hengrui Medicine Co., Ltd. is a pharmaceutical and healthcare enterprise engaged in pharmaceutical innovation and the R&D, production, and promotion of high-quality drugs. Founded in 1970 and listed on the Shanghai Stock Exchange in 2000, the company had over 20,000 employees worldwide by the end of 2018. It is a well-known domestic supplier of anti-tumor drugs, surgical medications, and contrast agents, as well as the lead unit of the National Anti-tumor Drug Technology Innovation Industry-University-Research Alliance. The company has established the National Targeted Drug Engineering Technology Research Center and a Postdoctoral Research Station. In May 2018, Forbes released the list of the World's 100 Most Innovative Companies, with seven Chinese companies making the list, and Hengrui Medicine ranked 64th. In 2018, the company achieved operating revenue of 17.42 billion yuan and paid taxes of 3 billion yuan.

Stock Details

1. Key Indicators

  • Total Shares(W): 663719.99
  • Circulating A-Shares(W): 637900.23
  • Earnings Per Share(RMB): 0.8900
  • Net Assets Per Share(RMB): 8.9653
  • Operating Revenue(W RMB): 2318808.19
  • Total Profit(W RMB): 641200.78
  • **Net Profit Attributable to Parent(W RMB) **: 575116.95
  • Net Profit Growth Rate(%): 24.50
  • Weighted Return on Equity(%): 11.0900
  • Operating Cash Flow Per Share(RMB): 1.3730
  • Undistributed Profit Per Share(RMB): 5.7769
  • Capital Reserve Per Share(RMB): 1.9484

2. Main Business

The main business covers:

  • Development, manufacturing, and sales of formulations such as tablets, injections, capsules, and powder injections

3. Company Basic Information

  • Company Name: Jiangsu Hengrui Pharmaceuticals Co., Ltd.
  • Listing Date: 2000-10-18
  • Industry: Pharmaceutical Manufacturing
  • Address: No. 38 Huanghe Road, Economic and Technological Development Zone, Lianyungang City, Jiangsu Province
  • Website: https://www.hengrui.com/
  • Company Profile: The company was established as a joint stock limited company on April 28, 1997, with Lianyungang Pharmaceutical Industry Company as the main sponsor, jointly initiated by China National Pharmaceutical Industry Corporation, Lianyungang Pharmaceutical Industry Company Labor Union, Lianyungang Pharmaceutical Purchasing and Supply Station, and Lianyungang Kangyuan Pharmaceutical Co., Ltd. At the time of establishment, the company's total share capital was 61.9 million shares. In December 1998, Lianyungang Pharmaceutical Industry Company was restructured into Lianyungang Hengrui Group Co., Ltd. On May 5, 1999, the company approved the 1998 profit distribution plan. After the bonus share issue, the company's total share capital became 92.85 million shares. After the public issuance of 40 million RMB ordinary shares on September 7, 2000, the company's total share capital reached 132.85 million shares.

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 Jiangsu Hengrui Pharmaceutical Group Co., Ltd. General Legal Person 153818.42 24.11
2 Tibet Dayuan Enterprise Management Co., Ltd. General Legal Person 95275.23 14.94
3 Hong Kong Securities Clearing Company Ltd. Northbound Capital 48693.75 7.63
4 China Pharmaceutical Investment Co., Ltd. General Legal Person 18363.02 2.88
5 Qingdao Bosentai Technology Co., Ltd. General Legal Person 15951.12 2.50
6 Lianyungang Financial Holding Group Co., Ltd. General Legal Person 10771.79 1.69
7 China Securities Finance Corporation Ltd. Special Legal Person 9539.98 1.50
8 SSE 50 ETF Fund 8529.34 1.34
9 Huatai-PineBridge CSI 300 ETF Fund 7607.23 1.19
10 E Fund CSI 300 Healthcare ETF Fund 5598.15 0.88

5. Concept Sectors

  • H-Share
  • Tongdaxin 88
  • Immunotherapy
  • Generic Drugs
  • Assisted Reproduction
  • Innovative Drugs
  • Weight Loss Drugs
  • AI Healthcare

Remarks

  • Data update date: 2025-09-30
  • Data source: Public Market Information